vTv Therapeutics
vTv Therapeutics is a late-stage biopharmaceutical company focused on developing oral, small molecule drug candidates intended to help treat people living with diabetes and other chronic diseases.
Last updated September 10, 2026
AI crawler reads
No AI crawler has read this profile since Oct 28, 2026.
Overview
vTv Therapeutics (vTv) is a late-stage biopharmaceutical company focused on developing oral, small molecule drug candidates intended to help treat people living with diabetes and other chronic diseases. Its clinical pipeline is led by cadisegliatin, currently in a Phase 3 trial, a potential first-in-class oral liver-selective glucokinase activator being investigated for the treatment of type 1 diabetes (T1D). The company is committed to improving the lives of people with diabetes.
Products and positioning
late-stage biopharmaceutical company focused on developing oral, small molecule drug candidates intended to help treat people living with diabetes and other chronic diseases
cadisegliatin (TTP399)
a potential first-in-class oral liver-selective glucokinase activator being investigated for the treatment of type 1 diabetes (T1D), currently in a Phase 3 trial
Sources4 sources
Cite this profile: Cite the canonical profile. /brand-wiki/vtv-therapeutics · Editorial policy · How profiles are compiled